Uniphar Unveils Expanded Commercialization Platform
Uniphar, a prominent healthcare services company, has introduced an advanced platform that capitalizes on its extensive 55-year legacy. With a commitment to delivering specialized services to over 200 clients worldwide, Uniphar is reshaping the landscape of pharmaceutical and biotech commercialization.
Empowering Pharmaceutical Launches
This new platform is designed to assist pharmaceutical and biotech companies in effectively navigating the complexities inherent in product launches. It arrives in conjunction with the debut of Uniphar's seventh cell and gene therapy initiative for a respected global pharmaceutical firm.
Founded in 1967 by community pharmacists in Ireland, Uniphar has evolved through significant acquisitions and growth. Today, the company stands as a diversified entity focused on enhancing patient access to critical pharmaceutical products across the globe.
Expert Insights from Uniphar
Brian O'Shaughnessy, Chief Commercial Officer at Uniphar, articulates the pressing challenges in the pharmaceutical sector. He notes, "The hurdles faced by pharma and biotech companies can be extensive when it comes to launching groundbreaking therapies. As a result, many medicines go undistributed in regions with pressing patient needs."
Navigating Regulatory Landscapes
Uniphar's expertise positions it as a vital partner in overcoming the diverse regulatory challenges that companies confront. O'Shaughnessy elaborates, "Adapting to various regulations, research and development expenses, pricing pressures, and inadequate infrastructure are barriers that often hinder the launch of innovative medicines in complex markets. Our goal is to utilize our knowledge and specialized supply chain to facilitate these launches successfully."
Unlocking Potential in Europe
The European pharmaceutical market represents a significant opportunity, comprising 19% of the global market share, with growth anticipated by 2025. Research indicates a stark contrast, with 64% of new medicines launched in the U.S. between 2016 and 2021, compared to a mere 16.8% in Europe. This discrepancy presents both a challenge and an exceptional opportunity for pharmaceutical and biotech companies.
"Understanding the distinct regulations and needs across European markets is crucial for unlocking the potential of life-saving medicines. By adapting to the evolving pharmaceutical landscape over the past 25 years, we have developed a platform that simplifies these processes, thereby increasing access to medications for healthcare providers and patients alike," asserts O'Shaughnessy.
Commitment to Equitable Access in Cell and Gene Therapies
Projections indicate that by 2030, up to 60 new cell and gene therapies will be available for routine use. Uniphar remains at the forefront of addressing equitable access, aiming to ensure that these transformative therapies reach over 350,000 patients who could benefit from them.
In 2023, Uniphar successfully facilitated access to complex therapies for 500 patients across 50 countries, showcasing its expertise in cell and gene therapies. As a leading global authority, Uniphar’s pharma division aligns multifunctional teams and infrastructure to support successful commercialization efforts.
Infrastructure for Life-Saving Innovation
"The initiatives led by Uniphar in the realm of cell and gene therapies exemplify the importance of having the right infrastructure in place to deliver complex, life-saving therapies to those in need," highlights O'Shaughnessy. He emphasizes the imperative of ensuring equitable access to these cutting-edge medicines to meet patient requirements effectively.
About Uniphar
Uniphar Group serves as a trusted partner for pharmaceutical, medtech, and biotech organizations, focusing on enhancing patient access to essential medicines worldwide. With a legacy of over 55 years, Uniphar has partnered with more than 200 multinational clients, building tailored solutions that respond to the shifting dynamics of the market.
Uniphar Pharma integrates Uniphar | Access, Uniphar | Medical, and Uniphar | Commercial, leveraging a wealth of experience to provide clients with end-to-end services that eliminate barriers to market entry and optimize therapeutic value globally.
Frequently Asked Questions
What is Uniphar's new commercialization platform?
Uniphar's new platform is designed to support pharmaceutical and biotech companies in successfully launching their products globally, leveraging their extensive industry experience.
How does Uniphar assist with regulatory challenges?
Uniphar helps companies navigate diverse regulatory requirements, reducing barriers that can impede the launch of innovative medicines in complex markets.
What opportunities does the European market present?
The European pharmaceutical market, accounting for 19% of the global share, offers significant potential for growth and expansion, particularly for innovative therapies.
How many patients have benefited from Uniphar's programs?
In 2023, Uniphar successfully delivered complex therapies to 500 patients across 50 countries, emphasizing their role in making advanced treatments accessible.
What is Uniphar's commitment to equitable access?
Uniphar is dedicated to ensuring equitable access to cell and gene therapies for all patients, with a focus on reaching those in need of innovative treatments.
